Eosinophilic Esophagitis- Pipeline Insight, 2025

This “Eosinophilic Esophagitis- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Eosinophilic Esophagitis: Understanding

Eosinophilic Esophagitis: Overview

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach. Eosinophils can be found in the esophagus in response to various stimuli or antigen. Eosinophilic esophagitis (EoE) is a chronic immune or antigen-mediated process. Clinically, it presents with various esophageal dysfunction, and pathologically, there is mucosal inflammation predominantly with eosinophils, which is confined to the esophagus only.

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus characterized by the presence of a high number of eosinophils, a type of white blood cell, in the esophageal tissue. This condition can affect individuals of all ages but is more commonly diagnosed in children and young adults. EoE is often associated with allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis, suggesting an allergic component to its pathogenesis. The signs and symptoms of EoE vary depending on the age of the patient. In children, symptoms may include difficulty feeding, failure to thrive, vomiting, and abdominal pain. Older children and adults often experience dysphagia (difficulty swallowing), particularly with solid foods, food impaction (when food gets stuck in the esophagus), chest pain that is not related to heart disease, and persistent heartburn that does not respond well to standard treatments for gastroesophageal reflux disease (GERD). Chronic inflammation can lead to the narrowing of the esophagus, further complicating swallowing.

The exact cause of EoE is not fully understood, but it is believed to result from a combination of genetic, environmental, and immune factors. Allergens from food or the environment are thought to play a significant role in triggering the immune response that leads to eosinophil accumulation in the esophagus. Common food triggers include dairy, wheat, eggs, soy, peanuts, and seafood. Inhaled allergens, such as pollen, may also contribute to the condition in some individuals. Pathophysiologically, EoE involves the infiltration of eosinophils into the esophageal epithelium, leading to inflammation and tissue damage. This immune response is driven by Th2-type helper T cells, which produce cytokines like interleukin-5 (IL-5) and interleukin-13 (IL-13) that promote eosinophil growth and activation. The chronic inflammatory process can cause remodeling of the esophageal tissue, including fibrosis and strictures, resulting in the clinical manifestations of the disease. Diagnosis of EoE is based on a combination of clinical symptoms, endoscopic findings, and histological examination of esophageal biopsies. During an endoscopy, characteristic features such as rings, furrows, white exudates, and strictures may be observed. Biopsies are taken to quantify the number of eosinophils in the esophageal tissue, with a count of 15 or more eosinophils per high-power field being indicative of EoE. Treatment typically involves dietary management to identify and eliminate trigger foods, use of proton pump inhibitors (PPIs) to reduce acid-related inflammation, and topical corticosteroids (swallowed rather than inhaled) to reduce eosinophilic inflammation. In some cases, esophageal dilation may be necessary to alleviate strictures and improve swallowing. Ongoing monitoring and adjustments to the treatment plan are often required to manage this chronic condition effectively.

'Eosinophilic Esophagitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eosinophilic Esophagitis pipeline landscape is provided which includes the disease overview and Eosinophilic Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Eosinophilic Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eosinophilic Esophagitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Eosinophilic Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve Eosinophilic Esophagitis.

Eosinophilic Esophagitis Emerging Drugs Chapters

This segment of the Eosinophilic Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Eosinophilic Esophagitis Emerging Drugs

APT-1011: Ellodi Pharmaceuticals

APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in clinical development, following successful completion of FLUTE I and FLUTE II. It has been granted orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis.

IRL201104: Revolo Biotherapeutics

IRL201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a number of preclinical models. It has successfully completed Phase I clinical development and has the potential to be the first Immune Resetting Asthma Drug (IMRAD). 1104 is a novel linear peptide, derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It may provide remission for many allergic diseases. 1104 engages a novel target on macrophages and is a first-in-class modulator of the macrophage response. This response engages not only the effector arm of the immune system, but the regulatory arm as well. Currently the product is in Phase II stage of development for the treatment of patients with eosinophilic esophagitis (EoE) and other Th2 allergic diseases.

AQ280: Aqilion

AQ280 is an oral, small-molecule, super selective JAK1 inhibitor. JAK1 is an enzyme, a kinase that accelerates inflammatory processes, which, among other things effects allergy and fibrosis. By inhibiting its mechanism, it is possible to reduce symptoms and disease development in chronic inflammatory diseases. Within the Regulus program, Aqilion is developing AQ280, which is a super selective JAK1 inhibitor, as a treatment of the chronic disease eosinophilic esophagitis. Data describing the pharmacokinetic profile, safety and tolerability of the drug candidate was evaluated between every dose escalation. Now, data has been collected for all dose groups and the database has been locked for statistical analysis. Currently the product is in Phase I stage of development for the treatment of patients with eosinophilic esophagitis (EoE).

Eosinophilic Esophagitis: Therapeutic Assessment

This segment of the report provides insights about the different Eosinophilic Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Eosinophilic Esophagitis

There are approx. 25+ key companies which are developing the therapies for Eosinophilic Esophagitis. The companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.

Phases

The report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Eosinophilic Esophagitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Eosinophilic Esophagitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Eosinophilic Esophagitis drugs.

Eosinophilic Esophagitis Report Insights

• Eosinophilic Esophagitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Eosinophilic Esophagitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Eosinophilic Esophagitis drugs?
• How many Eosinophilic Esophagitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eosinophilic Esophagitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Esophagitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eosinophilic Esophagitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ellodi Pharmaceuticals
• Revolo Biotherapeutics
• Aqilion
• Bristol-Myers Squibb
• EsoCap
• Pfizer
• Calypso Biotech
• Serpin Pharma
• Landos Biopharma

Key Products

• APT-1011
• IRL201104
• AQ280
• Cendakimab
• Mometasone
• Etrasimod
• CALY-002
• SP 16
• Omilancor

This product will be delivered within 1-3 business days.